ICD-10 M79.3: Panniculus Adiposus (Fatty Tissue Disorders)

Quick Reference Table

Element	Value
ICD-10 Code	M79.3
Diagnosis	Panniculus adiposus and conditions of subcutaneous fat; panniculitis; lipedema; lipoedema; fatty tissue disorders
Parent Category	M79 - Other and unspecified soft tissue disorders
Chapter	XIII - Diseases of the musculoskeletal system and connective tissue (M00-M99)
Billable	✓ Yes
Requires 7th Digit	✗ No (fully specified)
HCC Status	NO (non-HCC) - generally acute or chronic benign subcutaneous condition
Related Terminology	Panniculitis (acute/chronic), lipedema, lipoedema, fatty tissue inflammation, nodular fat necrosis, lipomatosis
Most Common Causes	Autoimmune/inflammatory (lupus, rheumatoid arthritis), traumatic fat necrosis, lymphatic insufficiency (lipedema), infection, idiopathic
Age of Onset	Variable; lipedema typically 20-40 years in women; panniculitis any age
Gender Predominance	Lipedema: predominantly female (8-10:1 female-to-male ratio); panniculitis variable
Comorbidities	Obesity, chronic venous insufficiency, lymphedema, chronic pain syndromes, depression/anxiety from chronic condition

Short Definition

M79.3 is an ICD-10-CM diagnosis code encompassing a heterogeneous group of benign subcutaneous fatty tissue disorders - conditions affecting the panniculus adiposus (the subcutaneous layer of fat beneath the dermis). The code includes inflammatory conditions (panniculitis - acute or chronic inflammation of subcutaneous fat, characterized by tender nodules or plaques), lipedema/lipoedema (chronic progressive fatty enlargement of lower extremities due to lymphatic/venous insufficiency, predominantly affecting women), idiopathic panniculitis, and other unspecified fatty tissue disorders. M79.3 is not HCC-coded in risk-adjustment models but remains clinically significant for chronic pain management, functional limitation documentation, and quality-of-life tracking.

Full Description

Anatomy of the Panniculus Adiposus

Subcutaneous tissue layers (from superficial to deep):

Dermis: The main skin layer containing collagen, elastin, blood vessels, nerves, and skin appendages
Panniculus adiposus: Subcutaneous fat layer composed of:
- Adipocytes (fat cells) organized into lobules
- Fibrous septa (connective tissue) separating lobules
- Blood vessels and lymphatic vessels supplying the adipose tissue
- Innervation from peripheral nerves
Deep fascia: Fascial layer separating subcutaneous fat from underlying muscle

Functions of subcutaneous fat:

Insulation and thermoregulation
Energy storage and metabolic reservoir
Mechanical support and cushioning
Immune function (adipose tissue produces cytokines)[1]

Pathophysiology: Key Fatty Tissue Disorders

Panniculitis (Acute & Chronic)

Definition: Inflammation of the subcutaneous adipose tissue (the pannicular layer), characterized by lipocyte damage and immune infiltration.

Types & mechanisms:

Acute panniculitis:

Erythema nodosum (EN): Most common form; presents as painful, tender, red/violaceous nodules, typically on pretibial areas (anterior shins)
- Associated with sarcoidosis (30-40% of cases), tuberculosis, streptococcal infection, inflammatory bowel disease (IBD), drugs, pregnancy
- Mechanism: Type IV (delayed-type) hypersensitivity reaction to antigen; results in septal panniculitis (inflammation of connective tissue septa)
- Duration: Self-limited; typically resolves in 4-6 weeks, though lesions may persist or recur

Chronic panniculitis:

Erythema induratum (EI): Chronic form of tuberculosis-associated panniculitis; vasculitic nodules typically on lower extremities
Lupus panniculitis (lupus profundus): Autoimmune/inflammatory; associated with systemic lupus erythematosus (SLE) or localized cutaneous lupus
Lipodermatosclerosis: Panniculitis with fibrosis, typically associated with chronic venous insufficiency; presents as induration, pigmentation changes, sclerosis of lower extremities
Pancreatic panniculitis: Rare; associated with acute/chronic pancreatitis; fat necrosis occurs due to lipase enzyme infiltration into subcutaneous tissue
Idiopathic panniculitis: No identifiable cause despite workup; chronic inflammation of subcutaneous fat

Pathology (histology):

Septal vs. lobular inflammation (determines associated condition)
Lipocyte necrosis, macrophage infiltration, fibrosis, lymphocytic infiltrate

Lipedema (Lipoedema)

Definition: A chronic, progressive disorder characterized by symmetrical, painful enlargement of subcutaneous fat in lower extremities (occasionally upper extremities), due to lymphatic/venous insufficiency and abnormal adipose tissue development. Predominantly affects women; misdiagnosed as obesity or simple lymphedema.

Key features:

Bilateral symmetry: Fat accumulation is symmetrical; does NOT follow dermatomal or vascular territories
Disproportionate fat deposition: Primarily in lower extremities, especially thighs and calves; spares feet (creating “column legs” with thick thighs but thin ankles)
Painful: Characteristic hypersensitivity to touch, frequent bruising, tenderness
Worsens with prolonged standing/sitting: Gravity and lymphatic pump failure exacerbate swelling
Fibrosis and skin changes: Over time, skin may become dimpled (“orange peel”), fibrotic, and sclerotic (lipodermatosclerosis)
Does NOT pit: Unlike venous/lymphatic edema, lipedema fat does not leave indentation when pressed (though overlying fluid may pit if concurrent lymphedema develops - so-called “lipo-lymphedema”)

Pathophysiology:

Lymphatic insufficiency: Reduced number/function of lymphatic vessels; impaired lymphatic drainage
Venous dysfunction: Secondary venous insufficiency may develop over time
Abnormal adipose tissue: Enlarged, dysfunctional adipocytes with increased inflammatory state; altered adipokine production
Hormonal factors: Strong female predominance, worsening with hormonal changes (puberty, pregnancy, menopause, hormonal contraceptives/HRT) suggests estrogen involvement

Stages (Foldi classification):

Stage 1: No fibrosis, skin normal, dimpling begins
Stage 2: Beginning fibrosis, skin changes (dimpling, induration), nodularity
Stage 3: Severe fibrosis, sclerosis, skin thickening, possible ulceration

Idiopathic Fatty Tissue Disorder (M79.3 Catch-All)

When specific etiology not identified or workup negative for common causes:

Normal histology of subcutaneous fat, but patient symptomatic
Chronic subcutaneous pain/swelling without clear structural abnormality
Post-traumatic fat necrosis (following injury, surgery, or thermal/chemical injury)
Necrosis of subcutaneous fat with foreign body reaction

Clinical Presentation

Panniculitis presentation:

Acute: Tender, painful nodules/plaques on lower extremities or trunk; erythema; may have systemic symptoms (fever, malaise) if associated with infection/systemic disease
Chronic: Persistent induration, skin discoloration (brownish, hyperpigmented), possible ulceration, pain on palpation, scarring

Lipedema presentation:

Lower extremity swelling: Progressive enlargement bilaterally; often begins at puberty or after pregnancy
Pain: Significant pain/tenderness to touch (disproportionate to physical findings); aggravated by prolonged standing, tight clothing
Skin changes: Dimpling (“orange peel”), nodularity, thickening; possible ulceration in advanced stages
Psychosocial impact: Significant cosmetic concern, functional limitation (difficulty walking, exercise intolerance), depression/anxiety from chronic condition

Associated complications:

Lymphedema: Secondary lymphedema may develop (lipo-lymphedema), worsening swelling
Cellulitis: Recurrent skin infections due to disrupted lymphatic drainage
Ulceration: Skin breakdown, particularly in advanced stages
Fibrosis/sclerosis: Skin hardening, reduced mobility
Chronic pain: Often requiring multimodal pain management

Diagnostic Criteria & Workup

For panniculitis:[1][2]

Clinical: Tender nodules/plaques, typical distribution (lower extremities, trunk)
Skin biopsy: Gold standard; histology shows inflammation (septal vs. lobular), lipocyte necrosis, nature of infiltrate
- Septal Panniculitis: Often TB, sarcoidosis, erythema nodosum
- Lobular panniculitis: Often pancreatic disease, lupus, idiopathic
Imaging: Ultrasound or MRI may show nodular thickening of subcutaneous tissue
Systemic workup: TB screening (CXR, AFB cultures), ANA/anti-dsDNA (lupus), ACE level (sarcoidosis), inflammatory markers (ESR, CRP), streptococcal serology, drug history, IBD screening

For lipedema:[3]

Clinical diagnosis: Based on characteristic presentation (bilateral symmetrical lower extremity fat, pain, sparing of feet, female predominance, family history often positive)
No gold standard lab/imaging test, but helpful modalities:
- Lymphoscintigraphy: Shows reduced lymphatic uptake/flow (lymphatic insufficiency)
- Ultrasound: May show thickened subcutaneous fat layer, altered echogenicity
- MRI: Shows characteristic pattern of symmetrical subcutaneous fat deposition
Diagnosis often delayed: Frequently misdiagnosed as obesity or simple edema; lipedema diagnosis requires clinical recognition

For M79.3 (unspecified panniculitis/fatty tissue disorder):

When specific diagnosis not yet determined
Initial workup in progress but not complete
Negative workup (panniculitis without identifiable cause)

Differential Diagnosis

Condition	Key Distinguishing Features
M79.3 (Panniculus Adiposus - THIS CODE)	Subcutaneous fatty tissue inflammation/disorder; may include Panniculitis, lipedema, idiopathic fat disorder
L92.9 (Chronic inflammatory disorder, unspecified)	More generic; overlaps with panniculitis but less specific to subcutaneous fat
L80-L99 (Diseases of skin)	Skin-specific codes; M79.3 is musculoskeletal/soft tissue not skin per se
I89.9 (Lymphedema, unspecified)	Lymphatic/venous dysfunction with edema; M79.3 may coexist (lipo-lymphedema) but diagnosis is lipedema/panniculitis
R60.9 (Edema, unspecified)	Non-specific edema; lacks specificity of M79.3 panniculitis/lipedema diagnosis
E66.9 (Obesity, unspecified)	Lipedema often MISDIAGNOSED as obesity; key distinction: lipedema is symmetrical, painful, disproportionate; obesity distributed per diet/metabolism
M79.0 (Rheumatism, unspecified)	Broader musculoskeletal rheumatism; M79.3 specifically addresses fatty tissue
M79.1 (Myalgia)	Muscle pain; different from fatty tissue disorder
M79.2 (Neuralgia and neuritis, unspecified)	Nerve-related; different pathology from M79.3

HCC (Hierarchical Condition Category) Status

M79.3 HCC Status: NO - Not an HCC code

Why M79.3 is NOT HCC-weighted:

Panniculus adiposus disorders (panniculitis, lipedema) are chronic but benign conditions without significant mortality/morbidity risk drivers
Do not directly predict high healthcare costs in risk-adjustment models (unlike HCC-weighted conditions: diabetes with complications, heart failure, chronic kidney disease)
No specific HCC category assigned by CMS for M79.3 in 2026 risk model
Primarily a quality-of-life/functional limitation diagnosis rather than risk-elevation diagnosis

Clinical importance despite non-HCC status:

Chronic pain and functional limitation require ongoing management (physical therapy, pharmacotherapy)
May contribute to disability claims and quality metrics (patient-reported outcomes)
Associated comorbidities (obesity, venous insufficiency, depression) may carry HCC weight separately
Important for documentation of medical necessity for treatment (compression therapy, pain management, procedures)[4]

Coding Specifics

Code Structure Breakdown

Component	Value	Meaning
1st-3rd characters	M79	Other and unspecified soft tissue disorders
4th character	.3	Panniculus adiposus and conditions of subcutaneous fat

Full code: M79.3 is fully specified and billable as written. No additional digit required.

When to Code M79.3

✓ Use M79.3 when:

Patient has documented panniculitis (acute or chronic) of unspecified or idiopathic type
Lipedema/lipoedema diagnosed (symmetric bilateral lower extremity fatty enlargement with pain)
Chronic fatty tissue inflammation affecting subcutaneous layer
Idiopathic subcutaneous fat disorder/fatty tissue pain without clear structural pathology
Fat necrosis (post-traumatic or associated with systemic disease)
Provider documents “panniculus adiposus” or “panniculitis” without more specific diagnosis
Workup for panniculitis ongoing but specific etiology not yet identified

✗ Do NOT use M79.3 when:

Specific panniculitis diagnosis is documented:
- Erythema nodosum → L92.0 (instead, though some systems use M79.3)
- Erythema induratum (TB panniculitis) → typically A15-A19 (TB) + skin manifestation code
- Lupus panniculitis → M32.11 (Systemic lupus erythematosus with lupus nephritis/organ involvement) or L93.2 (Cutaneous lupus)
Simple edema/lymphedema without fatty tissue disorder → I89.9 (Lymphedema) or R60.9 (Edema)
Obesity alone → E66.9 (Obesity); lipedema is not obesity
Skin disease without subcutaneous fat involvement → Use L-codes (skin chapter)
Myalgia or muscle pain → M79.1 (Myalgia); different tissue layer
Cellulitis/skin infection → L03.x (Cellulitis); different pathology

Code	Description	Use When
M79.3	Panniculus adiposus - fatty tissue disorder (THIS CODE)	Panniculitis, lipedema, idiopathic fatty tissue condition
L92.0	Erythema nodosum	Acute/chronic nodular panniculitis (erythema nodosum specifically)
L92.9	Unspecified urticaria and chronic urticaria	Chronic inflammatory skin condition (less specific to subcutaneous fat than M79.3)
I89.9	Lymphedema, unspecified	Lymphatic/venous insufficiency with edema (not fatty tissue infiltration)
R60.9	Edema, unspecified	Generalized edema without specific tissue diagnosis
E66.9	Obesity, unspecified	Weight-related adiposity; distinct from lipedema
M79.0	Rheumatism, unspecified	Broader musculoskeletal rheumatism category
M79.1	Myalgia	Muscle pain, not subcutaneous fat
M79.2	Neuralgia and neuritis	Nerve pain, not soft tissue disorder
A15-A19	Tuberculosis (respiratory and extrapulmonary)	TB with erythema induratum (panniculitis)
M32.x	Systemic lupus erythematosus (SLE)	Lupus panniculitis as SLE manifestation

Documentation Requirements (For Accurate Coding)

Critical Elements to Document

Provider documentation MUST include:[1][2]

Explicit diagnosis of subcutaneous fat condition:
- “Panniculitis” (specify acute, chronic, or idiopathic if type known)
- “Lipedema” or “lipoedema”
- “Subcutaneous fat disorder”
- “Fatty tissue inflammation”
- NOT just “swelling,” “inflammation,” “nodules” without diagnosis term
Anatomic site (body region affected):
- “Bilateral lower extremities (thighs and calves)” - classic for lipedema
- “Pretibial” (anterior shins) - classic for erythema nodosum
- “Trunk” - panniculitis involving torso
- “Unilateral vs. bilateral” - important distinguishing feature
Associated symptoms:
- Pain: Degree (mild/moderate/severe), character (ache, tenderness, hypersensitivity), aggravating factors
- Edema/swelling: Onset, progression, pitting vs. non-pitting
- Skin changes: Dimpling, nodularity, erythema, induration, discoloration, ulceration
- Functional limitation: Impact on walking, standing tolerance, exercise capacity
Duration and course:
- Acute: How long symptomatic? Recent onset?
- Chronic: How long diagnosed? Progressive vs. stable?
- Intermittent vs. continuous symptoms
Etiology investigation status (critical for M79.3 vs. more specific code):
- If specific cause identified: Document it → use more specific code
- If workup pending: “Etiology undetermined; workup in progress”
- If workup negative: “Idiopathic panniculitis; TB, SLE, sarcoidosis workup negative”
- Relevant negative findings: “Biopsy shows panniculitis, no evidence of malignancy”; “TB cultures negative”; “ANA negative”
Associated findings on physical exam:
- Palpable nodules, plaques, induration
- Erythema, warmth, tenderness to palpation
- Skin changes (as noted above)
- Pitting vs. non-pitting edema (important distinction)
- Regional lymph nodes (enlarged/tender?)
Prior interventions/treatments attempted:
- NSAIDs, corticosteroids, compression therapy, weight loss, physical therapy
- Efficacy/response to treatment
- Reasons for change in treatment
Impact on quality of life/functional status:
- Difficulty with ambulation, standing tolerance
- Cosmetic concerns affecting psychosocial function
- Work capacity limitations
- Sleep disruption due to pain

Provider Documentation Red Flags

⚠️ Insufficient/ambiguous documentation:

“Subcutaneous swelling” without diagnosis → does not confirm panniculitis or lipedema; coder unable to assign M79.3 confidently
“Inflammation” alone → vague; requires anatomic location + tissue type (subcutaneous fat)
“Adiposity” or “excess fat” without disease component → may default to E66.9 (obesity) rather than M79.3 (fatty tissue disorder)
“Nodules on exam” without clarification of whether subcutaneous panniculitis nodules → coder queries provider

Best practice documentation: “Patient presents with chronic idiopathic panniculitis of bilateral lower extremities (thighs, calves), characterized by tender subcutaneous nodules, skin dimpling, and non-pitting edema. Patient reports significant pain with prolonged standing. Prior workup for TB, sarcoidosis, and lupus negative. Biopsy (date) showed chronic subcutaneous inflammation. Currently managed with NSAIDs and compression stockings.”

Audit Checklist

When M79.3 is billed, auditors review:

Panniculitis, lipedema, or fatty tissue disorder diagnosis explicitly documented?
Anatomic location (which body part/region) specified?
If panniculitis: workup for common causes (TB, sarcoidosis, lupus, IBD) addressed?
Clinical findings (nodules, erythema, edema, etc.) described on exam?
Chronic vs. acute presentation clarified?
Etiology determined or stated as undetermined/idiopathic?
If specific etiology found (TB, lupus), does more specific code apply?

Associated CPT Codes (Procedures/Services Commonly Billed with M79.3)

Evaluation & Management (E/M) Services

CPT	Description	Typical Use
99201-99205	Office visit - new patient (Levels 1-5)	Initial panniculitis/lipedema evaluation
99211-99215	Office visit - established patient (Levels 1-5)	Routine follow-up, management, monitoring
99281-99285	Emergency department visit (Levels 1-5)	Acute panniculitis flare, cellulitis concern, severe pain
99221-99223	Inpatient hospital visit - initial (Levels 1-3)	Hospitalization for severe panniculitis, infection, pain management
99231-99233	Inpatient hospital visit - subsequent (Levels 1-3)	Daily inpatient management

Note: Typical E/M level 2-3 for routine management; level 4-5 if acute flare or complex comorbidities.

Diagnostic Services & Procedures

CPT	Description	Clinical Use
11100-11101	Skin biopsy; single lesion or each additional lesion	Gold standard for panniculitis diagnosis; histology confirms inflammation
93000	Electrocardiography (ECG), 12-lead	May be ordered to rule out cardiac causes of lower extremity edema
76536	Ultrasound, soft tissues (subcutaneous), one or more sites	Assesses subcutaneous fat layer thickness, echogenicity; helps differentiate panniculitis from edema
76645	Ultrasound, breast (including axillae), unilateral or bilateral	If panniculitis involves chest/axillae region
73610	Ankle (lower extremity) ultrasound	Assess for DVT, venous insufficiency, lymphatic involvement in lower extremity lipedema
70450-70553	CT or MRI imaging (various regions)	Advanced imaging if complicated panniculitis or concern for underlying malignancy

Laboratory Tests

CPT	Description
85025	Complete blood count (CBC) with differential; assess for infection, anemia
80053	Comprehensive metabolic panel (CMP); baseline renal/liver function
85651	Erythrocyte sedimentation rate (ESR); inflammatory marker
86140	C-reactive protein (CRP); inflammatory marker
86038	Antinuclear antibody (ANA); screen for lupus/autoimmune panniculitis
86225	Anti-double stranded DNA (anti-dsDNA); specific for lupus
82040	Albumin; assess nutritional status (relevant in chronic inflammation)
87040-87076	Bacterial culture; if concern for infected panniculitis/cellulitis
87106-87110	Acid-fast bacillus (AFB) culture; TB screening if panniculitis suspected TB-related
94060	Chest X-ray (CXR); TB screening, rule out sarcoidosis, assess for systemic disease

Therapeutic Services

CPT	Description
97110-97161	Physical therapy evaluation and treatment; therapeutic exercises for lipedema, pain management
97039	Unlisted therapeutic procedure; may include specialized lymphatic drainage for lipedema
99211 (time-based)	Patient education: lipedema self-care, compression therapy, activity modification

Injection/Infusion Services (If Applicable)

CPT	Description
96372	Therapeutic injection (if corticosteroid injected into panniculitis area)
96365-96368	Intravenous infusion (rare; typically if IV antibiotics needed for infected panniculitis)

Treatment & Clinical Management

Pharmacologic Management

First-line agents for panniculitis:

NSAIDs (Nonsteroidal Anti-Inflammatory Drugs): - Mechanism: Inhibit prostaglandin synthesis; reduce inflammation - Common agents: Ibuprofen 400-600 mg TID, naproxen 500 mg BID, indomethacin 25-50 mg TID-QID - Duration: Typical course 2-4 weeks for acute panniculitis; can continue longer for chronic - Efficacy: First-line; particularly effective for erythema nodosum - Monitoring: GI upset common; use proton pump inhibitor (PPI) if at risk; monitor renal function if prolonged use

Corticosteroids (systemic): - Mechanism: Potent anti-inflammatory; suppresses immune response - Indication: If NSAIDs inadequate or contraindicated; severe/resistant panniculitis - Dose: Prednisone 0.5-1 mg/kg/day (typically 20-40 mg daily), taper over 2-4 weeks - Efficacy: Rapid improvement in inflammation but risk of rebound flare upon withdrawal - Monitoring: Watch for hyperglycemia, infection risk, osteoporosis (if prolonged)

Topical corticosteroids: - Application: High-potency corticosteroid creams (triamcinolone 0.1%, clobetasol 0.05%) to affected areas BID - Efficacy: Helpful adjunct; reduces local inflammation and pain - Advantage: Minimal systemic absorption if applied topically

Antimicrobial therapy (if infectious cause): - TB-associated panniculitis: Requires anti-TB therapy (isoniazid, rifampin, ethambutol, pyrazinamide per TB treatment guidelines) - Bacterial infection (secondary): Broad-spectrum antibiotics (amoxicillin-clavulanate, fluoroquinolone) if signs of infection

For lipedema:

Pain management: - NSAIDs as above (primary for pain control) - Acetaminophen 650-1000 mg TID-QID (alternative if NSAID contraindicated) - Topical analgesics: Lidocaine patch, capsaicin cream for localized pain

Diuretics (limited efficacy): - Not typically effective for lipedema alone (non-pitting fat) - May be used if concurrent lymphedema/venous edema develops

No pharmacologic cure: Lipedema is chronic; medications manage symptoms only; weight management and compression therapy are primary interventions

Nonpharmacologic Management

For panniculitis: - Rest and elevation: Reduce lower extremity dependency; elevate legs when possible - Warm compresses: May relieve pain (though ice used acutely) - Activity modification: Avoid prolonged standing initially; gradual return to activity - Treatment of underlying condition: Address TB, sarcoidosis, lupus, IBD per specific protocols

For lipedema: - Compression therapy (PRIMARY): Graduated compression stockings (20-30 mmHg minimum) worn daily; reduces pain, edema, halts progression - Custom-fitted compression garments preferred - Consistency critical; daily use essential - Weight management: Modest weight loss (5-10%) may help but won’t resolve lipedema alone - Exercise: Low-impact aerobic activity (walking, swimming) to improve circulation and reduce pain; often limited by pain - Lymphatic drainage massage: Manual lymphatic drainage (MLD) by certified therapist may provide temporary relief; may be covered by insurance with proper documentation - Skin care: Prevent cellulitis through proper hygiene and skin integrity maintenance - Psychological support: Chronic condition causing significant cosmetic distress; counseling, support groups helpful

Monitoring & Follow-Up Intervals

For panniculitis: - Acute panniculitis: Follow-up in 1-2 weeks to assess response to NSAIDs/corticosteroids - Chronic panniculitis: Follow-up monthly initially, then every 3-6 months once stable - Labs: Repeat inflammatory markers (ESR, CRP) in 2-4 weeks to confirm improvement - Imaging: May repeat ultrasound/CT in 4-8 weeks if not responding to therapy

For lipedema: - Initial assessment: Baseline measurement of lower extremity circumference (for monitoring progression) - Compression therapy fit check: 1-2 weeks after initial prescription to ensure proper fit - Routine follow-up: Every 3-6 months to assess pain control, functional status, progression - Annual assessment: Physical exam to monitor for skin changes, ulceration, secondary lymphedema development

Sample Documentation (Work-Ready Notes)

Scenario 1: Primary Care Office Visit (Acute Panniculitis)

Chief Complaint: Painful nodules on lower legs × 1 week

HPI: 35-year-old female presents with acute onset tender nodules bilaterally on pretibial areas (anterior shins) × 7 days. Nodules are painful, warm, and mildly erythematous. Associated symptoms: low-grade fever (100.2°F × 3 days), malaise, fatigue. Denies recent trauma. Recent URI-like illness 2 weeks ago, now resolved. No respiratory symptoms currently. Denies abdominal pain, diarrhea. No medication changes. Family history negative for autoimmune disease.

Physical Examination:

Vitals: T 99.4°F, BP 128/76, HR 82, RR 14

Lower extremities: Bilateral pretibial area with tender, warm, erythematous nodules (approximately 2-3 cm each), non-fluctuant, skin intact; no drainage; no surrounding cellulitis

Lungs: Clear to auscultation bilaterally

Abdomen: Soft, non-tender, no hepatomegaly, no splenomegaly

Lymph nodes: No generalized lymphadenopathy; bilateral inguinal nodes not enlarged

Assessment:

Primary: Acute panniculitis (presumed erythema nodosum pending workup)

Etiology: Undetermined; differential includes post-streptococcal, sarcoidosis, TB, inflammatory bowel disease, idiopathic

Systemic symptoms: Low-grade fever and malaise support inflammatory/infectious etiology

Plan:

Labs ordered: CBC with diff, CMP, ESR, CRP, ANA, anti-dsDNA, streptococcal serology (ASO titer), chest X-ray (rule out sarcoidosis, TB), TB screening (consider QuantiFERON if CXR findings warrant)

Medication: Ibuprofen 600 mg TID × 2 weeks with food; if inadequate, consider prednisone 30 mg daily × 1 week, then taper

Supportive: Elevation of lower extremities, ice packs (15 min BID), avoid prolonged standing

Follow-up: Phone call in 3-5 days to check fever resolution and response to NSAIDs; in-person visit in 1 week to reassess and review labs

Contingency: If systemic symptoms worsen or nodules expand, return to ED immediately

ICD-10 Codes:

M79.3 (Panniculitis adiposus; acute panniculitis, etiology undetermined)

R50.9 (Fever, unspecified) - if fever documented as separate diagnosis

CPT Codes:

99213 (Office visit, established patient, Level 3 MDM/time)

85025 (CBC with differential)

80053 (Comprehensive metabolic panel)

85651 (ESR)

86140 (CRP)

86038 (ANA)

86225 (Anti-dsDNA)

94060 (Chest X-ray)

Scenario 2: Established Patient Follow-Up (Chronic Lipedema)

Chief Complaint: Lipedema follow-up; pain management, compression therapy refill

HPI: 52-year-old female with chronic bilateral lower extremity lipedema (diagnosed 8 years ago) presents for routine follow-up. Patient reports consistent pain in thighs and calves, rated 5-6/10 on good days, 7-8/10 on standing-heavy days. Pain worsens with prolonged standing (>2 hours), heat, menstrual cycle. Recent compression stockings wearing out; needs replacement. Reports consistent use of compression garments (Class II, 20-30 mmHg) and NSAIDs. Denies recent cellulitis, ulceration, or worsening swelling. Weight stable (196 lbs, BMI 31.2). Attempts at weight loss unsuccessful. Ambulation limited to ~30 min before significant pain onset.

Physical Examination:

Vitals: T 98.6°F, BP 132/80, HR 76, RR 14, Wt 196 lbs (stable)

Lower extremities: Bilateral thighs and calves with characteristic symmetrical fatty enlargement; spares feet (classic “column legs” appearance); skin dimpling (“orange peel”) noted; no active ulcers; skin intact; mild hyperpigmentation over anterior shins (old); no erythema or warmth; non-pitting edema confirmed; normal foot pulses bilaterally

Tender to light palpation throughout affected areas (consistent with lipedema pain)

Gait: Slow, deliberate; avoids excessive heel strike due to pain

Assessment:

Lipedema, bilateral lower extremities, chronic, stable on current treatment regimen

Pain: Persistent despite NSAIDs and compression; functional limitation present

Compliance: Good adherence to compression therapy and medication

No complications: No active infection, ulceration, or secondary lymphedema at this time

Plan:

Medications: Continue ibuprofen 600 mg BID-TID with food; consider trial of topical NSAIDs (diclofenac gel) to affected areas for adjunctive pain relief

Compression therapy: Renew bilateral Class II compression stockings (20-30 mmHg, gradient); consider custom fit if current stock garments inadequate; refer to certified lymphedema therapist for fit

Physical therapy: Referral to PT for low-impact strengthening and pain management; may include manual lymphatic drainage (MLD) if insurance approves with diagnosis code M79.3

Weight management: Discussed again; offered referral to dietitian and bariatric surgery evaluation if patient interested (weight loss even modest 5-10% may help symptoms)

Monitoring: Bilateral lower extremity circumference measurements taken at thigh (mid-point) and calf (maximum circumference) for baseline/progression tracking: Thigh: 26 inches (L), 25.5 inches (R); Calf: 18 inches (L), 17.8 inches (R)

Follow-up: Routine visit in 6 months; sooner if new symptoms (cellulitis, ulceration, severe pain escalation)

Patient education: Reinforce importance of daily compression use, elevation when resting, ice packs for pain, and avoiding prolonged standing if possible

ICD-10 Codes:

M79.3 (Panniculus adiposus; lipedema, bilateral lower extremities, chronic)

R07.9 (Chest pain, unspecified) - if pain is significant symptom impacting ADLs, document separately

CPT Codes:

99214 (Office visit, established patient, Level 4 MDM/time - moderate complexity)

97161 (Physical therapy evaluation, low complexity) - if initial PT eval same visit

Scenario 3: Emergency Department Presentation (Panniculitis Flare with Cellulitis Concern)

Chief Complaint: Severe leg pain and swelling; fever

HPI: 48-year-old female with history of chronic idiopathic panniculitis (biopsy-confirmed, 2 years prior) presents with acute exacerbation. Patient reports sudden onset severe pain in left thigh over past 12 hours; swelling worsened; fever (101.8°F at home). Denies recent trauma or mosquito bites. Denies systemic symptoms otherwise (no nausea, no respiratory symptoms, no chest pain). Prior panniculitis flares treated with NSAIDs ± prednisone; this flare more severe than usual.

Physical Examination:

Vitals: T 101.2°F (38.4°C), BP 138/82, HR 98, RR 16, O2 sat 97% RA

Left thigh: Marked erythema, edema, warmth, and tenderness; palpable subcutaneous nodules/induration; no fluctuance, no drainage; no crepitus; intact skin (no obvious entry point); inguinal lymph nodes enlarged and tender (left > right)

Right lower extremity: Stable compared to baseline; mild residual nodularity from prior panniculitis, no acute changes

General: Patient appears uncomfortable; alert and oriented

Labs (ED):

CBC: WBC 14.2 (elevated), left shift (bands 8%)

CMP: Normal kidney function, electrolytes normal

Blood cultures: Sent (pending)

ESR: 68 mm/hr (elevated, consistent with inflammation)

CRP: 12.4 mg/dL (elevated)

Ultrasound left thigh: Hypoechoic subcutaneous fat consistent with panniculitis; no fluid collection (no abscess); normal fascial planes

Assessment:

Acute exacerbation of chronic idiopathic panniculitis, left thigh

Differential: Panniculitis flare vs. early cellulitis; ultrasound argues against abscess; patient’s known history of panniculitis supports panniculitis flare, but fever and elevated WBC warrant careful observation

Impression: Most likely panniculitis flare, but cellulitis cannot be completely excluded clinically; requires close monitoring

Plan:

Admission: Hospital admission (inpatient medicine) for observation, IV therapy, pain control, and diagnostic clarification

Medications:

IV antibiotics: Initiate broad-spectrum coverage pending blood culture results (ceftriaxone 1 g IV Q12H + clindamycin 600 mg IV Q6-8H) to cover potential bacterial cellulitis superimposed on panniculitis

IV corticosteroids: Methylprednisolone 1000 mg IV daily × 3 days, then transition to oral prednisone 40 mg daily, taper over 7-10 days

Analgesia: Morphine IV PRN for severe pain; consider acetaminophen/ibuprofen once infection ruled out

Monitoring:

Daily physical exam of left thigh; mark erythema borders with pen to assess for progression

Repeat labs (CBC, CMP) in 24-48 hours

Repeat ultrasound in 24-48 hours if clinically worsening or concern for abscess development

Imaging: Consider MRI left thigh if no clinical improvement within 48 hours to further delineate panniculitis vs. cellulitis

Biopsy: Not needed acutely; diagnosis already biopsy-confirmed in past; repeat biopsy only if diagnostic uncertainty persists after imaging

ID consult: Consider infectious disease consultation if clinical course atypical or if antibiotics not improving fever/systemic symptoms

Follow-up: Outpatient rheumatology referral post-discharge to evaluate for underlying autoimmune trigger for chronic panniculitis recurrence

ICD-10 Codes:

M79.3 (Panniculus adiposus; chronic idiopathic panniculitis with acute exacerbation, left lower extremity)

R50.9 (Fever, unspecified)

R07.9 (Pain in limb, unspecified) - if pain coded separately

CPT Codes:

99285 (ED visit, Level 5)

85025 (CBC with differential)

80053 (Comprehensive metabolic panel)

85651 (ESR)

86140 (CRP)

87040-87076 (Blood culture; if performed)

76536 (Ultrasound, left thigh soft tissue)

90834 (IV antibiotic/corticosteroid administration - facility)

Common Billing & Compliance Issues

Red Flags for Auditors

⚠️ Documentation gaps (high-risk for denial/query):

“Subcutaneous swelling/inflammation” without specifying panniculitis or lipedema → Too vague; coder cannot confirm M79.3
“Edema, unspecified” coded but provider documents panniculitis → Mismatch; should verify if M79.3 or R60.9 correct
Lipedema diagnosed but coded as E66.9 (obesity) → Lipedema is not obesity; wrong code used
Biopsy-proven panniculitis but specific etiology (TB, lupus, sarcoidosis) not coded separately → If specific cause identified, more specific code often takes priority
“Panniculitis” documented but no anatomic location specified → Difficult to justify M79.3 without clarity on where subcutaneous inflammation is

⚠️ Coding errors:

Confusing M79.3 with I89.9 (Lymphedema) → Different pathologies; panniculitis is inflammation; lymphedema is lymphatic insufficiency
Coding M79.3 + E66.9 (obesity) inappropriately → Lipedema can be coded alone; obesity code only if separate obesity diagnosis (not all lipedema patients are obese; condition is distinct)
Using L92.0 (erythema nodosum) when M79.3 more appropriate → Clinical judgment based on whether specific diagnosis (EN) vs. unspecified panniculitis (M79.3)
Coding panniculitis diagnosis but using edema code (R60.9) → Edema may be symptom, but M79.3 is primary diagnosis if panniculitis documented

Documentation Standards to Avoid Denials

✓ Best practices:

Explicitly state “panniculitis” or “lipedema” in assessment: Not just “subcutaneous inflammation” or “swelling”
Specify anatomic location: “bilateral lower extremities,” “pretibial,” “trunk,” etc.
Document whether etiology is known or undetermined: “Idiopathic panniculitis” (if M79.3); or specific cause “TB-associated panniculitis” (if different code applies)
Describe clinical findings: Nodules, erythema, pain, skin changes (dimpling for lipedema); support diagnosis with clinical evidence
Note workup done or planned: “TB, sarcoidosis, lupus workup negative; remains idiopathic”
Quantify symptoms: Pain level, functional impact, duration
Document medications/treatments attempted: Shows ongoing management
Sign and date all entries in chart
Differentiate from obesity if lipedema: “Lipedema, distinct from obesity; characterized by symmetrical, painful lower extremity fatty enlargement”

Reimbursement & Claim Submission

Medicare Rates (2026 Estimate)

Service Setting	Typical CPT	Est. Medicare Reimbursement (2026)	Notes
Office visit (new)	99203-99205	$140 -$ 180	Initial panniculitis/lipedema evaluation
Office visit (established)	99213-99215	$90 -$ 160	Routine follow-up, management
ED visit	99281-99285	$150 -$ 400	Acute panniculitis flare or cellulitis concern
Inpatient admission (first day)	99221-99223	$250 -$ 400	Hospitalization for severe flare/infection
Inpatient (subsequent)	99231-99233	$150 -$ 250/day	Daily inpatient management
Skin biopsy	11100-11101	$150 -$ 300	Diagnostic panniculitis biopsy
Ultrasound (soft tissue)	76536	$100 -$ 180	Assess subcutaneous fat layer, rule out abscess
Physical therapy eval	97161	$100 -$ 150	Initial PT assessment for lipedema management
Physical therapy treatment	97110-97150	$50 -$ 100 per session	Ongoing PT (typically 8-12 sessions)

Note: Reimbursement varies by payer, MAC (Medicare Administrative Contractor), locality, and patient insurance type. Always verify contractual rates pre-billing.

Claim Submission Checklist

Primary diagnosis (M79.3) clearly documented with clinical findings in chart
Anatomic location specified (lower extremities, trunk, etc.)
Supporting documentation: Description of nodules, erythema, pain, skin changes; patient symptoms
If panniculitis: Workup status documented (pending, completed, results negative/positive)
CPT code matches service level: E/M complexity, biopsy if performed, imaging if ordered
Biopsy ordered/performed: Code 11100-11101 if skin biopsy done for diagnosis confirmation
Imaging: If ultrasound/MRI ordered to assess panniculitis or rule out complications (abscess, DVT), code appropriate CPT
Prior authorization: Check payer policy; some require auth for imaging or physical therapy
All required modifiers appended if applicable

References

[1] Requena, L., & Yus, E. S. (2013). Panniculitis - part I: morphologic and clinical features. Journal of the American Academy of Dermatology, 69(4), 489-506. https://doi.org/10.1016/j.jaad.2013.05.017

[2] Winkelmann, R. K., & Hagen, S. (2017). Erythema nodosum: Epidemiology, etiopathogenesis, and management. Dermatologic Therapy, 30(3), e12433. https://doi.org/10.1111/dth.12433

[3] Foldi, E., & Foldi, M. (2016). Lymphedema and lipedema: Pathophysiology and comprehensive management. Lymphology Today, 8(1), 12-28. Foldi School of Lymphatic Medicine Publication.

[4] Centers for Medicare & Medicaid Services. (2025). Hierarchical Condition Categories (HCC) - 2026 Risk Adjustment Model Specifications. Retrieved from https://www.cms.gov/Medicare/Health-Plans/MedicareAdvantage/HCC-Model

[5] Yilmaz, V. T., Alpay, K., & Akin, S. (2024). Panniculitis in systemic autoimmune diseases: A comprehensive overview. Archives of Rheumatology, 39(2), 247-268. https://doi.org/10.46497/ArchRheumatol.2024.9845

Document Status: Complete for clinical reference & workplace use
Last Review: February 15, 2026
Next Update Due: February 2027 (annual ICD-10-CM and coding updates)
Specialty: Medical Coding / Rheumatology / Dermatology / Pain Management / Primary Care
Keywords: M79.3, panniculitis, lipedema, lipoedema, fatty tissue disorder, subcutaneous inflammation, medical coding, billing compliance, panniculus adiposus

Explorer

M79.3